Medtronic Is About to Report Its First Earnings Since Spinning Off MiniMed. Should You Buy the Stock Before Nov. 24?

Source The Motley Fool

Key Points

  • Medtronic concluded its spin-off of MiniMed in October.

  • Investors will expect rising sales and stabilizing margins in its upcoming report.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

Medtronic (NYSE:MDT), one of the world's largest medical device makers, will post its next earnings report on Nov. 24. It will mark its first earnings report after it spun off its diabetes unit, MiniMed (NASDAQ:MMED), and fully removed its business from its balance sheet.

Woman working on a laptop at a desk with financial trading charts on a large monitor.

Image source: Getty Images.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

What are analysts expecting?

In fiscal 2023 and fiscal 2024 (which ended in April 2024), Medtronic's earnings declined as it struggled with supply chain constraints, inflation, forex headwinds, regulatory challenges for its diabetes business, and lumpy post-pandemic recovery in elective procedures. Tougher competition, quality control issues, and new GLP-1 drugs exacerbated that pressure.

But in fiscal 2025 and fiscal 2026, its earnings grew again as it stabilized its costs, expanded its higher-growth cardiovascular and neuroscience businesses, and spun off MiniMed. In fiscal 2026, its revenue grew 5.8% organically, marking its strongest top-line growth in a decade. For fiscal 2027, it expects its revenue to rise another 7.25%-7.75%.

Should you buy Medtronic before Nov. 24?

For the third quarter of fiscal 2027, analysts expect Medtronic's revenue to rise 6% year over year but for its adjusted EPS to dip 2%. Its cardiovascular and neuroscience businesses should remain strong. Still, the completion of its MiniMed spin-off (which concluded on Oct. 15), its reinvestment in higher-growth platforms, early-stage manufacturing costs for newer cardiovascular devices, and a few recent acquisitions are squeezing its margins.

Medtronic's stock looks cheap at 17 times forward earnings and pays a forward yield of 2.9%. However, I'd wait to see how well it grows organically -- and how it's handling the margin pressure -- before buying the stock and assuming it's a safe blue chip dividend play.

Should you buy stock in Medtronic right now?

Before you buy stock in Medtronic, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medtronic wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 21, 2026.

Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Medtronic. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Spot Gold Breaches Four Key Levels, Putting $3,500 at Risk as Technicals Enter Oversold Alert Zone International gold prices extended their accelerating decline. On November 20, spot gold (XAUUSD) briefly dipped to around $3,514.6, having fallen for multiple consecutive trading days an
Author  TradingKey
Yesterday 10: 12
International gold prices extended their accelerating decline. On November 20, spot gold (XAUUSD) briefly dipped to around $3,514.6, having fallen for multiple consecutive trading days an
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 20, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
Author  Mitrade
Yesterday 03: 38
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
placeholder
TradingKey Daily Market Brief: Three Major US Indexes Drop Over 2%, Anthropic Gains 17% on DebutTracking Market TrendsTradingKey - All three major U.S. stock indices fell more than 2%, with the Nasdaq Composite Index (IXIC) down 2.25% to 23,879.20 points; the Dow Jones Industrial Average (DJIA)
Author  TradingKey
Yesterday 01: 30
Tracking Market TrendsTradingKey - All three major U.S. stock indices fell more than 2%, with the Nasdaq Composite Index (IXIC) down 2.25% to 23,879.20 points; the Dow Jones Industrial Average (DJIA)
placeholder
Gold Price Forecast: XAU/USD regains ground below $3,700, outlook remains fragileGold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
Author  FXStreet
Nov 19, Thu
Gold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
Nov 19, Thu
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
goTop
quote